Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 15Head & Neck 11Thoracic 7Dermatologic 7Gynecologic 4Sarcoma 3Other hematologic neoplasm 3CNS 3Plasma cell 2Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 101Endometrial Neoplasms 74Uterine Cervical Neoplasms 63Carcinoma, Non-Small-Cell Lung 56Colorectal Neoplasms 50Melanoma 49Triple Negative Breast Neoplasms 42Carcinoma, Renal Cell 41Stomach Neoplasms 37Squamous Cell Carcinoma of Head and Neck 35Fallopian Tube Neoplasms 33Breast Neoplasms 33Pancreatic Neoplasms 27Neoplasms 25Esophageal Neoplasms 24Carcinoma, Transitional Cell 24Neoplasm Metastasis 23Carcinoma, Hepatocellular 20Lung Neoplasms 19Carcinoma, Ovarian Epithelial 19Small Cell Lung Carcinoma 18Head and Neck Neoplasms 18Urinary Bladder Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 17Prostatic Neoplasms 14Cholangiocarcinoma 13Carcinoma, Merkel Cell 11Kidney Neoplasms 10Mesothelioma 9Uterine Neoplasms 8

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × pembrolizumab × Gynecologic × Clear all
NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Virginia Commonwealth University

Phase 2 Terminated
4 enrolled 8 charts
Gynecologic

Recurrence, Endometrial Neoplasms

NCT04713514 2024-12-02

TEDOVA

ARCAGY/ GINECO GROUP

Phase 2 Active not recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT05635344 2024-04-17

A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia

Imperial College London

Phase 2 Recruiting
20 enrolled
Gynecologic

Recurrence, Gestational Trophoblastic Disease

NCT02440425 2022-10-07

Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
42 enrolled 14 charts
Gynecologic

Carcinoma, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡